Sulbaksit

Quick links to important sections

Sulbaksit

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sulbaksit

Quick Facts

Property Description
Active Ingredients Ampicillin and Sulbactam
Form Sterile powder for solution for injection
Pharmacological Class beta-lactam/beta-lactamase inhibitor combination
General Purpose Treatment of serious bacterial infections
Origin Semi-synthetic

Sulbaksit: Definition and Pharmacological Classification

Sulbaksit is a fixed-dose, semi-synthetic combination antibacterial preparation used exclusively to treat serious bacterial infections. It is classified within the group of beta-lactam/beta-lactamase inhibitor combination antibiotics, a category recognized for its clinical importance.


This medicine is strictly a prescription-only medicine designed specifically to overcome key defense mechanisms bacteria use to resist conventional antibiotic treatment. Belonging to the beta-lactam class, the fixed combination structure provides a potent dual therapeutic approach essential for effectively controlling systemic infections, particularly those caused by resistant organisms. This formulation is widely employed in hospital settings to manage severe, established infections.

What is Sulbaksit Made of? Composition and Differentiation

Sulbaksit’s action relies on the verified synergistic combination of two distinct active ingredients: the beta-lactam antibiotic Ampicillin and the protective mechanism-based inhibitor Sulbactam.


The Ampicillin component, an aminopenicillin, directly achieves bactericidal action by preventing bacteria from properly constructing their cell walls. The crucial Sulbactam component is not an antibiotic but serves as an irreversible inhibitor of bacterial beta-lactamase enzymes. This specific pairing is clinically recognized for expanding the spectrum of activity against many beta-lactamase-producing pathogens, ensuring its efficacy where Ampicillin alone would fail. The inclusion of Sulbactam enhances the clinical utility of Ampicillin against resistant bacteria.

Dosage Form and General Purpose

Sulbaksit is supplied as a sterile powder for solution for injection, intended exclusively for parenteral administration, meaning it is given via intravenous (IV) or intramuscular (IM) injection.


This specialized formulation and route of administration are selected to ensure the medicine rapidly achieves high and reliable concentrations within the patient’s bloodstream, a critical requirement for managing severe systemic infections. The general purpose of Sulbaksit is to leverage its synergistic effect to successfully target and eliminate susceptible bacteria, providing reliable antimicrobial treatment.

What side effects are possible with Sulbaksit?

Possible Side Effects and Safety Information

Sulbaksit (Ampicillin/Sulbactam) is a combination antibiotic and its safety profile is characterized by adverse reactions common to the penicillin class. Factual safety information is structured by System Organ Class (SOC) and frequency of occurrence.

Common Adverse Reactions (occurring in ge1% of patients in clinical trials) include Diarrhea, Rash, and localized reactions such as Pain at the injection site or Thrombophlebitis following intravenous administration. Other reported systemic reactions include nausea, vomiting, candidiasis, and headache.


Serious and Clinically Significant Adverse Reactions

  • Hypersensitivity: Severe, and occasionally fatal, hypersensitivity (anaphylactic) reactions have been reported. The risk is higher in individuals with a known history of penicillin or cephalosporin allergy. Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been documented in post-marketing experience.
  • Gastrointestinal: The product is associated with the risk of Clostridium difficile-associated diarrhea (CDAD), which can range from mild diarrhea to fatal colitis. This may occur up to two months or more after cessation of therapy.
  • Hepatotoxicity: Hepatic dysfunction, including cholestatic jaundice and hepatitis, has been reported. Hepatic function should be monitored in patients with pre-existing hepatic impairment. A history of cholestatic jaundice associated with this product is a contraindication.
  • Hematologic: Adverse effects on the blood and lymphatic system, such as anemia, thrombocytopenia, and eosinophilia, have been reported.

Safety Restrictions and Population Considerations

The use of Sulbaksit is contraindicated in individuals with a history of serious allergic reactions to penicillin or cephalosporin antibiotics, or a history of cholestatic jaundice/hepatic dysfunction associated with the drug. Caution is warranted in patients with mononucleosis, as a high incidence of rash is associated with ampicillin use in this condition. Renal impairment alters the elimination kinetics of both components; thus, dosage adjustments are required for patients with severely impaired renal function to avoid accumulation.

Overdose and Emergency Response

Overdose and When to Seek Help

The official prescribing information for Sulbaksit details clinical manifestations of overdose focused primarily on the central nervous system. Overexposure is specifically associated with the potential for neurological adverse reactions, including the occurrence of convulsions and seizures. Regulatory documents indicate this risk is related to the attainment of high cerebrospinal fluid (CSF) levels of beta-lactams within the nervous system.

A key population consideration is that patients with severe impairment of renal function (Creatinine clearance le30 mL/min) are at an increased risk of toxicity due to the prolonged serum concentrations of the drug components.

Immediate Emergency Action

Regulatory guidance mandates that emergency medical attention must be sought immediately in the event of a suspected overdose. Urgent medical help is required if the individual exhibits severe life-threatening signs.

Specifically, emergency services (e.g., 911) must be called immediately if the person has experienced collapse, a seizure, severe difficulty in breathing, or cannot be awakened.

Management and Observation

There is no specific antidote listed for the Sulbaksit combination. Management requires general symptomatic treatment and supportive care. Ampicillin may be removed from circulation by hemodialysis as a documented procedural intervention. Hospital monitoring is required following any serious overdose event or intervention.

Therapeutic Uses of Sulbaksit

What Sulbaksit Treats: Main Uses and Benefits

Sulbaksit is considered relevant in clinical settings involving serious bacterial infections, particularly those affecting deep tissue structures. Its primary therapeutic use includes managing complicated infections of the skin and skin structures, intra-abdominal infections, and gynecological infections. The medication is applied when supportive symptom management is appropriate to address acute, disruptive symptom patterns like pronounced local pain, swelling, and high systemic fever. The use is relevant for providing supportive relief in situations where bacterial resistance may affect other treatment options.

It is commonly used when infection is caused by or suspected to be caused by bacteria that are resistant to standard penicillin antibiotics. This application assists with treatment by addressing strains that may affect other therapeutic options. It may also be part of symptomatic management that helps address symptoms related to infectious risk following high-risk procedures like abdominal or pelvic surgery.

“The use is relevant for providing supportive relief during difficult episodes of infection, and may help patients cope more steadily with symptom fluctuations.”


Quick Fact: Support for Symptoms Related to Serious Infections

Symptom Domain General Patient Benefit
Systemic Distress (Fever, Chills) Contributes to easing the overall symptom load
Localized Inflammation (Pain, Swelling) Provides support that helps ease the overall symptom burden
Surgical Prophylaxis (Infection Risk) Supports general well-being during symptomatic phases

Eligibility and Restrictions for Use

Sulbaksit (Ampicillin/Sulbactam) is subject to specific population eligibility rules defined by regulatory authorities. The medicine is contraindicated in patients with a history of serious hypersensitivity reactions, such as anaphylaxis, to any beta-lactam antibacterial drugs, including penicillins and cephalosporins. It must also not be used by individuals who have experienced cholestatic jaundice or liver dysfunction previously linked to Sulbaksit.

For specific conditions, use is restricted. The medicine is not recommended for patients with infectious mononucleosis. Individuals with impaired renal function require careful dose frequency adjustment. Caution is also advised for those with a history of hepatic impairment, as monitoring may be required during treatment.

Eligibility rules for age groups are defined by official labeling: Safety and efficacy are not established for infants younger than 1 year or 2 months, depending on the infection type. During pregnancy, use is only permitted if the prescribing physician determines it is clearly needed, and caution is advised if administered during lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sulbaksit (Ampicillin and Sulbactam) defines interactions based on formal pharmacokinetic and procedural constraints. No formal drug-drug contraindications are listed in the official label, though specific combination restrictions exist.

Key Documented Interactions

Interacting Substance Official Regulatory Outcome Interaction Type
Probenecid Increases and prolongs serum concentrations of both active components due to a formal decrease in renal tubular secretion. Pharmacokinetic
Methotrexate Decreases Methotrexate clearance, officially leading to an increased risk of toxicity. Exposure Modification
Aminoglycosides Must be administered at separate injection sites at least 1 hour apart to prevent documented in vitro mutual inactivation. Procedural / Timing
Anticoagulants Use may produce additive effects on coagulation parameters and platelet function. Pharmacodynamic

Official Interaction Statements

  • Bacteriostatic medicines, such as tetracyclines, are noted to potentially interfere with the bactericidal effect of the penicillin component, representing a form of pharmacodynamic antagonism.
  • The label notes that administration has been associated with reported cases of reduced effectiveness of estrogen-containing oral contraceptives.
  • In patients with renal impairment, the clearance kinetics of both Sulbactam and Ampicillin are similarly affected, which alters the overall exposure pattern of the medicine.
  • The use of copper reduction methods for urinary glucose testing (e.g., Clinitest) may result in false-positive results due to documented drug-test interference.

Mechanism of Action

How Sulbaksit works


Modulating Signal Transduction via Kinase Inhibition

This domain describes how Sulbaksit modulates intracellular signaling sequences by initiating the suppression of key intracellular enzymes, such as Janus Kinases ( JAKs). By selectively targeting these molecules, the compound modifies early molecular steps that influence subsequent cellular responses, resulting in modifications of signaling cascades within the immune and inflammatory systems.


Regulating G- Protein Coupled Receptor ( GPCR) Activity

Sulbaksit operates within domains involving receptor-mediated signaling by acting upon specific GPCRs and their associated intracellular proteins. This interaction on the Gq signaling axis alters pathway activity and feedback regulation within targeted cells, reducing the signaling output driven by specific mediators and thereby modifying the activity profile of associated physiological systems.

Dosage and Administration Information

How to Use Sulbaksit: Administration Guidelines

Sulbaksit (Ampicillin-Sulbactam) is administered exclusively through parenteral routes, meaning it must be given as an intravenous (IV) injection or a deep intramuscular (IM) injection. This method ensures the medicine achieves adequate concentrations quickly, and is typically carried out in a hospital or clinic setting.


Standard Dosing and Frequency

Administration is based on a fixed 2:1 ratio of ampicillin to sulbactam, maintaining this ratio across all standard doses. The typical single adult dose ranges from 1.5 g to 3 g (total ampicillin plus sulbactam content) and is usually administered in divided doses every six or eight hours. The total daily dosage of the sulbactam component should not exceed 4 g.


Preparation and Administration Specifics

The medicine is supplied as a sterile powder that requires reconstitution with a suitable sterile diluent, such as sterile water for injection, before use. When given intravenously, the injection must be administered either slowly over at least 10 to 15 minutes or as an infusion over 15 to 30 minutes. For IM injection, a 0.5% lidocaine solution may be used as the diluent to help minimize local discomfort.


Duration and Population Adjustments

The course of treatment generally lasts 5 to 14 days, or until 48 hours after the patient's fever and other signs of infection have resolved. For patients with renal impairment, the frequency of administration must be adjusted (e.g., extended to every 12 or 24 hours) based on the degree of kidney function, while the individual dose amount remains unchanged.

Recent Clinical Evidence

Research evidence / Overview of Studies for Sulbaksit


Evidence for Use in Intra-abdominal Infections

Clinical trials have widely explored the use of Sulbaksit in adult patients experiencing conditions associated with acute episodes, specifically those involving organs within the abdomen. Researchers primarily used Randomized Controlled Trials (RCTs), which was evaluated in comparison to other treatments. Outcomes monitored included the rate of clinical success (a measured endpoint defined by the study protocol) and the rate at which the targeted bacteria were eradicated. Research highlights changes measured during the study period related to the outcomes linked to inflammatory or irritative states. However, evidence is limited by sample sizes that were limited in some groups, and the foundational research may reflect older therapeutic standards, meaning certain contemporary comparisons are not fully established.


Evidence for Use in Skin and Skin Structure Infections

Research employed Phase 3 RCTs and observational studies for conditions affecting the skin and soft tissues. Studies monitored outcomes linked to inflammatory states, including treatment failure and long-term outcomes monitoring physiological strain or stress in high-risk groups. Studies report how symptoms evolved in the observed populations, measuring the defined clinical success endpoint. Limitations exist: observational data may introduce variability across studies, and the results apply only to the populations studied.


Evidence for Use in Gynecological Infections

Research used comparative clinical trials to explore conditions involving heightened symptoms in women. Studies explored clinical clearance and eradication of susceptible organisms. The research record indicates that for some of the designated susceptible organisms, the sample sizes were limited, and dedicated comparative evidence is lacking in recent publications specifically for this indication.


Research Focus on Severe Respiratory Tract Infections

The medicine was evaluated in severely ill adults, including older adults, using meta-analyses and comparative RCTs. Researchers monitored clinical success and patient outcomes monitoring physiological strain or stress. Data show patterns related to outcomes, but findings were mixed when compared against certain newer treatments. Certainty remains low for definitive long-term outcomes, and evidence quality varies across studies.


Long-Term Outcomes and Follow-up

The majority of research studies focusing on episodes where symptoms become more noticeable have follow-up durations that were limited to the treatment period (up to Day 28). Evidence exploring outcomes beyond 90 days, or systemic or functional imbalance over many months, is not fully established.


Evidence in Special Populations

Sulbaksit was studied for pediatric patients (including infants and children) and older adults across various indications. Research exploring appropriate outcomes for these groups has been conducted. However, the evidence for very specific, high-risk groups within these populations may be limited, meaning the data for certain groups remain insufficient.


Understanding Current Research Gaps and Uncertainties

Despite the evidence supporting its regulatory use, research limitations frames exist. These include a lack of comparative evidence against some of the newest-generation antibiotics and variability in findings across different study designs. Overall, research highlights what is known — and what is still uncertain, reminding us that research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Ampicillin and Sulbactam Injection (MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Sulbaksit (FAQ)


Q: Is Sulbaksit considered a 'strong' or 'broad-spectrum' antibiotic?

A: Official information indicates that Sulbaksit is a combination medicine designed to treat serious bacterial infections. It combines ampicillin with sulbactam, a beta-lactamase inhibitor, which extends the medicine's activity against a range of susceptible bacteria that are otherwise resistant to ampicillin alone. It is active against many types of bacteria, including gram-positive, gram-negative, and some anaerobic organisms.

Q: What is the difference between Sulbaksit and other common beta-lactamase inhibitor antibiotics?

A: Sulbaksit is the specific combination of Ampicillin and Sulbactam, which is administered by injection (IV or IM). Other beta-lactamase inhibitor combinations use different core penicillin components and may be available in different forms, including pills. The choice of combination is based on factors determined by a healthcare provider.

Q: Does Sulbaksit treat viral infections, or only bacterial ones?

A: Sulbaksit is an antibacterial medicine and is indicated only for treating infections confirmed or strongly suspected to be caused by susceptible bacteria. Official information states it is not effective against infections caused by viruses.

Q: How quickly should a person start feeling better after starting Sulbaksit?

A: The time it takes to notice an improvement can vary widely depending on the type and severity of the infection. Regulatory documents indicate that treatment with Sulbaksit is typically continued until 48 hours after the patient's fever and other abnormal signs of infection have resolved.

Q: Is it normal to feel a bit of pain or irritation at the Sulbaksit injection site?

A: Injection site reactions are listed as common adverse reactions in the official safety information. This can include pain following an intramuscular (IM) injection or inflammation of the vein (thrombophlebitis) following an intravenous (IV) injection.

Q: Can Sulbaksit cause diarrhea, and what's the difference between mild diarrhea and a serious complication?

A: Diarrhea is a common side effect of Sulbaksit. However, a more serious condition called Clostridium difficile-associated diarrhea (CDAD) is also a risk that may be associated if a patient develops severe or persistent diarrhea. This more serious condition must be evaluated by a healthcare provider.

Q: How often are liver problems a side effect of Sulbaksit?

A: Official regulatory warnings note that hepatic dysfunction, including cholestatic jaundice and hepatitis, has been associated with the use of Sulbaksit. The product is strictly contraindicated for anyone with a past history of liver problems specifically caused by this drug. The official documentation does not list the frequency for this serious adverse event.

Q: Are there any common over-the-counter pain relievers that interact with Sulbaksit?

A: The official product label lists formal interactions with certain medicines like Probenecid and Methotrexate. It is recommended that patients review all concurrent medicines, including OTC products, with their healthcare provider to avoid potential interactions.

Q: Is Sulbaksit safe for children and teenagers, and does the dosage change?

A: The combination medicine is approved for use in pediatric patients one year of age and older for specific infections. For this population, official guidance requires that the dosage be based on the child’s body weight (mg/kg). Safety and efficacy are not established for infants younger than one year.

Q: How long can the side effect of severe diarrhea last after stopping Sulbaksit?

A: The severe form of diarrhea (CDAD) is officially noted to occur up to two months or more after a patient has finished taking an antibacterial agent. If severe or persistent diarrhea develops, patients should consult with a healthcare professional immediately.

Q: Why would a doctor switch a patient from an IV form of Sulbaksit to an oral antibiotic?

A: Switching from an intravenous (IV) antibiotic to an oral antibiotic is a common clinical practice, often called 'step-down' therapy. This allows patients who have shown clinical improvement to continue their treatment course, often outside of a hospital setting, usually by completing the therapy with a suitable oral medicine.

Q: Are there different brand names for the Ampicillin/Sulbactam combination besides Sulbaksit?

A: Yes, Ampicillin/Sulbactam is the generic name for this combination drug. Depending on the country, the drug may be sold under several different brand names; for instance, the combination is known by the brand name Unasyn in the United States.

Q: Can Sulbaksit cause tiredness or fatigue?

A: Official reports from post-marketing experience indicate that fatigue is a possible systemic reaction to this medicine. This is listed among the reported adverse reactions for the medicine.

Q: Is it normal for a rash to appear a few days into taking Sulbaksit?

A: A rash is listed as a common adverse reaction associated with Sulbaksit. Although the official label does not specify the exact timing for the typical onset of a common, non-severe rash, any developing rash should be reviewed with a healthcare professional.

Q: What are the specific signs of potential liver toxicity from Sulbaksit to watch for?

A: Patients should be aware of signs of possible liver disease, such as jaundice (a yellowing of the skin or the whites of the eyes), or other symptoms of cholestatic hepatitis, which are signs that necessitate a prompt evaluation by a healthcare provider.

Q: Is Sulbaksit known to cause headaches or dizziness?

A: Yes, the official list of adverse reactions includes headache as a common systemic reaction. Additionally, dizziness has been reported among the less frequent or post-marketing adverse effects associated with the medicine.

Q: How does Sulbaksit target resistant bacteria?

A: Sulbaksit is specifically designed to overcome a form of bacterial resistance. The Sulbactam component protects the Ampicillin from being broken down by bacterial enzymes called beta-lactamases, thus allowing the Ampicillin to kill the susceptible bacteria.

Q: Can Sulbaksit cause any mental or nervous system side effects like confusion or seizures?

A: Official reports include adverse effects on the nervous system. Convulsions, which are also known as seizures, and dizziness are listed among the effects reported in post-marketing experience.

Q: Can Sulbaksit affect my blood counts (white or red cells)?

A: Yes, adverse effects on the blood and lymphatic system (hematologic effects) have been reported, including anemia (affecting red cells), thrombocytopenia, and leukopenia. Monitoring of blood cell counts is advised during extended therapy.

Q: Why do some people experience a metallic or 'hairy' tongue while on this medication?

A: Changes to the tongue, such as glossitis (inflammation) or hairy tongue, are documented as less frequent systemic reactions to the combination drug. If these occur, they should be discussed with a healthcare provider.

Q: Can the injection of Sulbaksit be painful when given intramuscularly?

A: Pain at the injection site is listed as a common side effect. For intramuscular (IM) injection, the sterile powder may be mixed with a 0.5% lidocaine solution, which is used to help minimize local discomfort.

Q: Is it possible for a patient to be resistant to Sulbaksit?

A: Yes, as with all antibacterial medicines, it is possible for bacteria to be resistant to the combination. Sulbaksit is only effective against bacteria that are considered susceptible to it, and the use of any antibiotic can lead to the development of drug-resistant bacteria.

Q: Is Sulbaksit used for treating sexually transmitted infections (STIs)?

A: The official documentation indicates that Sulbaksit is active against certain organisms, such as Neisseria gonorrhoeae, which is a known cause of an STI. Its approved indications are specifically for skin, intra-abdominal, and gynecological infections.

Q: What happens if Sulbaksit is taken with alcohol?

A: The official regulatory label does not contain a specific contraindication or warning regarding the consumption of alcohol while using Sulbaksit. However, alcohol can potentially contribute to common side effects like headache or stomach upset, and its use with the medication is best clarified with a healthcare provider.

Q: Is Sulbaksit used for pre-surgical infection prevention (prophylaxis)?

A: Yes, Sulbaksit may be administered to patients to help prevent post-operative wound infections. This use is typically noted for patients undergoing certain abdominal or pelvic surgeries. A specific regimen is noted for administration around the time of anesthesia.

How should Sulbaksit be stored and disposed of?

How to Store and Dispose of Sulbaksit

The sterile powder for Sulbaksit (ampicillin and sulbactam) must be stored in its original container at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive heat and must not be frozen.

Stability After Reconstitution

The solution has limited stability once mixed. For solutions prepared with Sterile Water or 0.9% Sodium Chloride, it is stable for 8 hours at 25 C or 48 hours when refrigerated at 5 C. Solutions prepared with 5% Dextrose Injection are stable for 4 hours at either temperature.

Disposal and Safety

Official labeling mandates keeping the medicine out of the reach of children. Any unused portion or waste material must be disposed of according to local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sulbaksit found in:

A-Z Index: